Mindray(SZ:300760) Sou Hu Cai Jing·2025-10-16 09:41Group 1 - The core point of the news is the resignation of Cheng Minghe as Vice Chairman of Mindray Medical, which is part of the company's internal management optimization to adapt to new development needs [1][3][12] - The board restructuring is closely related to Mindray's plan to list on the Hong Kong Stock Exchange, including the appointment of Ernst & Young as the special auditing agency for the H-share issuance [3][12] - The company aims to issue overseas listed foreign shares (H-shares) and has made adjustments to its board structure to meet the listing requirements of the Hong Kong Stock Exchange [3][12] Group 2 - In the first half of 2025, Mindray Medical experienced a decline in both revenue and net profit, marking the first mid-year performance decline since its A-share listing in 2018 [4][5] - The company's revenue for the first half of 2025 was 16.743 billion yuan, a year-on-year decrease of 18.45%, while net profit was 5.069 billion yuan, down 32.96% [4][5] - The company expects a significant turning point in domestic business starting from the third quarter of 2025 as the medical industry enters a normalization phase [4] Group 3 - Cheng Minghe has played multiple key roles in Mindray Medical since its founding in 1991 and has served nearly 34 years in the company [6][10] - He has held various important positions, including Vice President of International Marketing and Co-CEO, and was recognized as one of the best CEOs in China by Forbes in 2020 [6][10] - Cheng Minghe's shareholding has decreased from 5.29% at the time of listing to 3.83% after a series of share reductions, indicating a shift from a core shareholder to a financial investor [8][9]